TD Cowen analyst Marc Frahm reiterated a Buy rating on Revolution (NASDAQ: RVMD).

The analyst commented: "Highlights From Management Huddle: Firing On All Cylinders; We hosted a post-Q2 earnings huddle with RVMD's CEO, CFO, CDO, and CCO. Topics included the breadth of daraxonrasib's EAP uptake, near- and long-term PDAC market expectations including novel combinations, pivotal paths in NSCLC, and the outlook in CRC (data in Q4). We continue to view Revolution as an emerging commercial leader in oncology and reiterate our Buy rating."

For an analyst ratings summary and ratings history on Revolution click here. For more ratings news on Revolution click here.

Shares of Revolution closed at $205.15 yesterday.